The grant will be used to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.
The grant will be used to further development of the existing preclinical research collaboration of the two companies.
*From the laboratory to rocket on the stock exchange – he turns medicine to gold.*
The Private Placement was significantly oversubscribed by both existing shareholders and new investors.
PCI Biotech has received clearance by the United States Food and Drug Administration (FDA) to include patients in the US.
The Private Placement was oversubscribed and attracted strong interest from both existing shareholders and new institutional investors.
Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team. Dr Rojkjaer will lead all clinical development strategy and execution and support the company’s efforts to identify opportunities to expand its pipeline of […]
Photocure delivers strong third quarter results.
The Norwegian Research Council granted Oslo Cancer Cluster member companies Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector funding through the Programme for User-Driven Research Based Innovation (BIA). In total, the Norwegian Research Council will grant 532 MNOK to 50 Norwegian companies, of which 10 are within biomedicine. Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector will receive between […]